Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technology forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% respectively for rifampicin, pyrazinamide, and isoniazid. In a pre-clinical study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same experimental period. Both treatment approaches had equivalent outcomes for resolution of inflammation associated with the infection of lungs and spleens. These results demonstrate how scalable technology could be used to manufacture nanoencapsulated drugs. The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB.

Gold nanoparticles from plant extracts and their bioactive compounds to treat various maladies have become an area of interest to many researchers. Acne vulgaris is an inflammatory disease of the pilosebaceous unit caused by the opportunistic bacteria Cutibacterium acnes and Staphylococcus epidermis. These bacteria are not only associated with inflammatory acne but also with prosthetic-implant-associated infections and wounds. Studies have hypothesised that these bacteria have a mutualistic relationship and act as a multispecies system. It is believed that these bacteria form a multispecies biofilm under various conditions and that these biofilms contribute to increased antibiotic resistance compared to single-species biofilms. This study aimed to investigate the antibacterial and wound healing potential of synthesised gold nanoparticles (AuNP_s) from an endemic South African plant, Plectranthus aliciae (AuNP_PAE), its major compound rosmarinic acid (AuNP_RA) and a widely used antibiotic, tetracycline (AuNP_TET). Synthesised gold nanoparticles were successfully formed and characterised using ultraviolet–visible spectroscopy (UV–vis), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ζ-potential), high-resolution transmission electron microscopy (HRTEM), and selected area electron diffraction (SAED), and they were investigated for stability under various biological conditions. Stable nanoparticles were formed with ζ-potentials of −18.07 ± 0.95 mV (AuNP_PAE), −21.5 ± 2.66 mV (AuNP_RA), and −39.83 ± 1.6 mV (AuNP_TET). The average diameter of the AuNP_s was 71.26 ± 0.44 nm, 29.88 ± 3.30 nm, and 132.6 ± 99.5 nm for AuNP_PAE, AuNP_RA, and AuNP_TET, respectively. In vitro, biological studies confirmed that although no antibacterial activity or biofilm inhibition was observed for the nanoparticles tested on the multispecies C. acnes and S. epidermis systems, these samples had potential wound closure activity. Gold nanoparticles formed with rosmarinic acid significantly increased wound closure by 21.4% at 25% v/v (≈29.2 µg/mL) compared to the negative cell control and the rosmarinic acid compound at the highest concentration tested of 500 µg/mL. This study concluded that green synthesised gold nanoparticles of rosmarinic acid could potentially be used for treating wounds.

It has been herein presented that a microemulsion, known to be an effective and safe drug delivery system following intravenous administration, can be loaded with traces of [⁶⁸Ga]Ga-PSMA-617 without losing its properties or causing toxicity. Following tolerated IV injections the capability of the microemulsion in altering [⁶⁸Ga]Ga-PSMA-617 distribution was presented at 120 min post injection based on its ex vivo biodistribution results.

The growing opioid crisis and persistent global health disparities underscore the urgent need for alternative therapeutic strategies. Cannabis, with its long-standing historical use and recent legislative developments, presents a potentially significant avenue for addressing these challenges. This review examines the evolving landscape of medicinal cannabis, drawing from historical ethnopharmacological data and contemporary scientific discussions. This review synthesized evidence from historical ethnobotanical records, peer-reviewed studies, and outcomes derived from recent Global Health events. These events facilitated discussions among diverse stakeholders, including healthcare professionals, policymakers, researchers, industry representatives, farmers, and patient advocates. Case studies and successful models from the USA and Africa, including the recent FDA approval for first-in-human clinical trials of a medicinal cannabis derivative for pancreatic cancer, were analysed. Successful models include collaborative platforms fostering stakeholder engagement, such as partnerships between African farmers and biotech firms to standardize cultivation. Successful models demonstrate the potential for adaptation and scaling in diverse healthcare settings. The FDA trial approval exemplifies progress in clinical translation. However, disparities persist, with patients within Africa facing systemic barriers to medical Cannabis certification and higher rates of punitive opioid discontinuation. Medicinal Cannabis presents a complex yet promising solution for reducing opioid-related mortality and addressing healthcare inequities. Implementing strategic frameworks like CORE (Care, Outreach, Research, Education) is essential for developing safe, high-quality, evidence-based cannabis products. Through fostering collaboration and addressing existing obstacles, the therapeutic potential of medicinal Cannabis can be harnessed to mitigate the opioid crisis and reduce global health disparities, effectively translating research from farm to bedside.